293 related articles for article (PubMed ID: 8500877)
1. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
Orr N; Robin G; Cohen D; Arnon R; Lowell GH
Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
[TBL] [Abstract][Full Text] [Related]
4.
Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
[No Abstract] [Full Text] [Related]
5. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.
Orr N; Arnon R; Rubin G; Cohen D; Bercovier H; Lowell GH
Infect Immun; 1994 Nov; 62(11):5198-200. PubMed ID: 7927807
[TBL] [Abstract][Full Text] [Related]
6. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
[TBL] [Abstract][Full Text] [Related]
8. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
[TBL] [Abstract][Full Text] [Related]
9. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.
Mallett CP; Hale TL; Kaminski RW; Larsen T; Orr N; Cohen D; Lowell GH
Infect Immun; 1995 Jun; 63(6):2382-6. PubMed ID: 7768627
[TBL] [Abstract][Full Text] [Related]
10. Outer Membrane Vesicles Derived from
Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q
Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809
[TBL] [Abstract][Full Text] [Related]
11. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
Kaminski RW; Wu M; Turbyfill KR; Clarkson K; Tai B; Bourgeois AL; Van De Verg LL; Walker RI; Oaks EV
Clin Vaccine Immunol; 2014 Mar; 21(3):366-82. PubMed ID: 24403527
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.
Fries LF; Montemarano AD; Mallett CP; Taylor DN; Hale TL; Lowell GH
Infect Immun; 2001 Jul; 69(7):4545-53. PubMed ID: 11401998
[TBL] [Abstract][Full Text] [Related]
14. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis.
Mitra S; Chakrabarti MK; Koley H
Vaccine; 2013 Jun; 31(31):3163-73. PubMed ID: 23684822
[TBL] [Abstract][Full Text] [Related]
15. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
[No Abstract] [Full Text] [Related]
16. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
Chisenga CC; Bosomprah S; Simuyandi M; Mwila-Kazimbaya K; Chilyabanyama ON; Laban NM; Bialik A; Asato V; Meron-Sudai S; Frankel G; Cohen D; Chilengi R
PLoS One; 2021; 16(5):e0252222. PubMed ID: 34043697
[TBL] [Abstract][Full Text] [Related]
17. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
Robin G; Cohen D; Orr N; Markus I; Slepon R; Ashkenazi S; Keisari Y
J Infect Dis; 1997 May; 175(5):1128-33. PubMed ID: 9129076
[TBL] [Abstract][Full Text] [Related]
18. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
Phalipon A; Tanguy M; Grandjean C; Guerreiro C; BĂ©lot F; Cohen D; Sansonetti PJ; Mulard LA
J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
[TBL] [Abstract][Full Text] [Related]
19. Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a.
Dharmasena MN; Hanisch BW; Wai TT; Kopecko DJ
Int J Med Microbiol; 2013 Apr; 303(3):105-13. PubMed ID: 23474241
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
Taylor DN; Trofa AC; Sadoff J; Chu C; Bryla D; Shiloach J; Cohen D; Ashkenazi S; Lerman Y; Egan W
Infect Immun; 1993 Sep; 61(9):3678-87. PubMed ID: 8359890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]